Program
F182112
Its studies are mostly in Lupus Erythematosus, Systemic · Multiple Myeloma, led by Lunan Pharmaceutical Group.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Lunan Pharmaceutical Group | 21 open or running | phase 1since Jul 21, 2021 | Jul 21, 2021 | Dec 31, 2027phase 1 · NCT07829614 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 21, 2021First study: phase 1 study in RecurrenceFirst studyNCT04984434 · 68 enrolled · China
- Sep 2, 2026Phase 1 study in Lupus Erythematosus, SystemicNCT07829614 · 64 planned · China
Ahead
- Dec 31, 2027Primary completion: phase 1 study in Lupus Erythematosus, SystemicNCT07829614
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07829614Lupus Erythematosus, Systemic · China | 1 | Recruiting | Dec 31, 2027 | 64 |
| NCT04984434Recurrence · China | 1 | UNKNOWN | Jul 30, 2023 | 68 |
How it is read
Names in the registry
- “F182112”, 2 entries
Conditions, from the studies’ own filings
- Lupus Erythematosus, Systemic, 1 study
- Multiple Myeloma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.